Clinical Trials Directory

Trials / Terminated

TerminatedNCT01522586

Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031

A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose-escalation Clinical Phase 1 Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
74 (actual)
Sponsor
Daewoong Pharmaceutical Co. LTD. · Industry
Sex
Male
Age
20 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of orally administrated DWP09031 in healthy male volunteers.

Conditions

Interventions

TypeNameDescription
DRUGDWP09031DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
DRUGPlaceboplacebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing

Timeline

Start date
2012-01-01
Primary completion
2013-05-01
Completion
2013-12-01
First posted
2012-01-31
Last updated
2014-02-13

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01522586. Inclusion in this directory is not an endorsement.